Centogene said it will use the funds to accelerate growth and expansion in the areas of genetic testing, pharmaceutical collaborations, and big-data solutions.
The partners will work to offer panel-based genetic characterization for a US-based cohort.
The company has installed Illumina's HiSeq X sequencing platform and expects to sequence 20,000 genomes by the end of next year.
The two companies plan to join their respective technologies in order to help clinicians better interpret genetic variant data.
The privately-held German firm also plans to offer genetic tumor profiling and noninvasive prenatal testing.
NEW YORK (GenomeWeb News) – LifeLabs Medical Laboratory Services today announced it has acquired the Canadian business of Centogene for an undisclosed amount.
While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.
Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.
In Nature this week: paternal age associated with de novo mutations in children, and more.
Nature News writes that researchers are still wrangling over the role of the p-value.